Researchers studied the factors associated with persistence or improvement after PIRA, as well as the effects of PIRA persistence on long-term outcomes in MS [1]. PIRA can be a sign of early SPMS, but PIRA events may regress over time. A cohort study was set up using data from 4,713 patients with relapsing-remitting MS who were enrolled in the MSBase registry between April 1995 and January 2024. One of the inclusion criteria was a minimum of 1 PIRA event, defined as 6-month confirmed disability progression (CDP) without relapse. The primary outcome was time to 6-month confirmed improvement after PIRA.
After a median follow-up of 6.8 years, the primary endpoint was met by almost a third of the investigated patients (n=1,507; 32%). When matched with patients with persistent PIRA (n=3,206) in a multivariate analysis, younger age (HR 0.98; 95% CI 0.98–0.99; P<0.0001), lower EDSS at baseline (HR 0.74; 95% CI 0.69–0.78; P<0.0001), and high-efficacy DMT use at baseline (HR 1.22; 95% CI 1.08–1.38; P<0.0015) were significantly associated with improvement after PIRA.
Investigated patients with persistent PIRA were at a substantially higher risk of reaching EDSS 6 and SPMS, compared with non-persistent PIRA: the HR was 5.19 (95% CI 4.05–6.67; P<0.0001) for reaching EDSS 6, and 3.51 (95% CI 2.42–5.08; P<0.0001) for reaching SPMS.
- Zhu C, et al. Risk factors associated with persistent progression independent of relapse activity (PIRA), and the association of persistent PIRA with disability progression in multiple sclerosis. Abstract O055, ECTRIMS 2024, 18–20 September 2024, Copenhagen, Denmark.
Medical writing support was provided by Michiel Tent
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Frexalimab shows favourable safety and efficacy in OLE Next Article
Tolebrutinib slows disability in non-relapsing secondary progressive MS »
« Frexalimab shows favourable safety and efficacy in OLE Next Article
Tolebrutinib slows disability in non-relapsing secondary progressive MS »
Table of Contents: ECTRIMS 2024
Featured articles
Revised McDonald criteria allow earlier and more precise MS diagnosis
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Online First
Revised McDonald criteria allow earlier and more precise MS diagnosis
Blood markers predict MS progression
High depression genetic burden associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
First-line moderate-efficacy DMTs show similar efficacy
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Frexalimab shows favourable safety and efficacy in OLE
Transfer of ocrelizumab into breastmilk is negligible
Ineffective response to EBV in MS not seen in similar diseases
Encouraging real-world results of AHSCT to treat aggressive MS
Tolebrutinib slows disability worsening in relapsing MS
High-dose simvastatin does not slow disability progression in SPMS
Gut microbiota modulates inflammation and cortical damage
Related Articles
August 22, 2022
Updated EAN-ECTRIMS guideline on pharmacological MS treatment
November 8, 2019
EAN guideline on palliative care
November 8, 2019
Siponimod delays time to wheelchair
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com